25 results on '"Sator, Paul"'
Search Results
2. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022.
- Author
-
Graier, Thomas, Salmhofer, Wolfgang, Jonak, Constanze, Weger, Wolfgang, Zikeli, Claudia, Gruber, Barbara, Sator, Paul, Prillinger, Knut, Mlynek, Alexander, Schütz‐Bergmayr, Martina, Richter, Leo, Ratzinger, Gudrun, Sassmann, Christoph, Painsi, Clemens, Häring, Nina, Wippel‐Slupetzky, Katharina, Skvara, Hans, Trattner, Hannes, Inzinger, Martin, and Bangert, Christina
- Abstract
Summary: Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real‐world psoriasis patients. Patients and Methods: Patient characteristics and the first‐year treatment effectiveness in biologic‐naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Leitlinie S1 für das Management postviraler Zustände am Beispiel Post-COVID-19.
- Author
-
Rabady, Susanne, Hoffmann, Kathryn, Aigner, Martin, Altenberger, Johann, Brose, Markus, Costa, Ursula, Denk-Linnert, Doris-Maria, Gruber, Samuel, Götzinger, Florian, Helbok, Raimund, Hüfner, Katharina, Koczulla, Rembert, Kurz, Katharina, Lamprecht, Bernd, Leis, Stefan, Löffler, Judith, Müller, Christian A., Rittmannsberger, Hans, Rommer, Paulus S., and Sator, Paul
- Abstract
Copyright of Wiener Klinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
4. Lokaltherapie der Psoriasis vulgaris.
- Author
-
Ramic, Lejla and Sator, Paul
- Abstract
Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
5. Topical treatment of psoriasis vulgaris.
- Author
-
Ramic, Lejla and Sator, Paul
- Abstract
Summary: Topical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role. To increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study.
- Author
-
Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, and Sator, Paul
- Published
- 2023
- Full Text
- View/download PDF
7. Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions.
- Author
-
Kern, Laura, Kleinheinrich, Luisa, Feldmann, Robert, Sator, Paul, Stella, Alexander, and Breier, Friedrich
- Subjects
ORAL lichen planus ,LICHEN planus ,DUPILUMAB ,BUCCAL administration ,DRUG eruptions ,MUCOUS membranes - Abstract
Lichen planus is a chronic, inflammatory, immune-mediated dermatosis affecting the patient's skin, scalp, mucous membranes, and nails. Drug-induced lichen planus is described after the administration of antimalarials, ß-blockers, methyldopa, NSAIDs, penicillamines, and sodium aurothiomalate. The use of biologicals such as adalimumab, etanercept, and infliximab has also been linked with the appearance of lichenoid eruptions in the recent past. In this case, we report on a patient developing oral and cutaneous lichen planus after the administration of dupilumab. The lichenoid lesions occurred after 11 months of the drug's administration and involved the buccal walls, trunk, and extremities. Dupilumab had been administered in an effort to counter severe atopic dermatitis exacerbations. Dupilumab is associated with a downregulation of T-helper 2 cell activation by blocking the Interleukin-4/Interleukin-13 pathway, so leading to a TH1/TH2 imbalance. This imbalance may cause a shift toward a TH1-mediated immune response and be an explanation for the drug-induced lichen planus. Dupilumab was discontinued, and the patient was treated with oral corticosteroids and UVB phototherapy, leading to a significant improvement in the lichen planus lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
- Author
-
Klein, Toni Maria, Blome, Christine, Kleyn, C. Elise, Conrad, Curdin, Sator, Paul G., Ståhle, Mona, Eyerich, Kilian, Radtke, Marc Alexander, Bundy, Christine, Cordey, Myriam, Griffiths, Christopher E. M., and Augustin, Matthias
- Subjects
PATIENT satisfaction ,APREMILAST ,PSORIASIS ,PSORIATIC arthritis ,TREATMENT effectiveness ,STANDARD deviations - Abstract
Introduction: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast. Objective: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics. Methods: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0–100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations. Results: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores. Conclusion: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Leitlinie S1: Long COVID: Differenzialdiagnostik und Behandlungsstrategien.
- Author
-
Rabady, Susanne, Altenberger, Johann, Brose, Markus, Denk-Linnert, Doris-Maria, Fertl, Elisabeth, Götzinger, Florian, de la Cruz Gomez Pellin, Maria, Hofbaur, Benedikt, Hoffmann, Kathryn, Hoffmann-Dorninger, Renate, Koczulla, Rembert, Lammel, Oliver, Lamprecht, Bernd, Löffler-Ragg, Judith, Müller, Christian A., Poggenburg, Stefanie, Rittmannsberger, Hans, Sator, Paul, Strenger, Volker, and Vonbank, Karin
- Abstract
Copyright of Wiener Klinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
10. Psoriasis and IgE-mediated allergy: correlation or mutual inhibition?: A prospective cohort study in patients with mild or moderate to severe psoriasis.
- Author
-
Essl, Anna, Loader, Dagmara, Feldmann, Robert, Steiner, Andreas, and Sator, Paul
- Abstract
Summary: Background: Psoriasis is an autoimmune disease caused by overactivation of T
H 1 (Type 1 helper cells) and TH 17 (T helper 17) cells. Overactivation of TH 1 cells inhibits the activity of TH 2 cells involved in type 1 allergies, therefore, psoriasis patients might be less affected by type 1 allergies. This study tested if allergies were less frequent in patients with moderate to severe than with mild psoriasis. Methods: Psoriasis patients at the study site reported possible allergy symptoms and were tested for common allergens by skin prick test and IgE levels. Psoriasis was classified by PASI scores (Psoriasis Area and Severity Index) as mild (PASI <10) or moderate/severe (PASI ≥10). Patients without systemic therapy were assessed separately. Fisher's exact test was used to test for differences. Results: A total of 97 patients were included, 21 with mild and 76 with moderate to severe psoriasis. Allergies were found in 27.8%, most commonly against dust mites (23.4%) and grasses (18.1%). Allergies were found in 23.8% of the patients with mild vs. 29.0% allergic patients with moderate to severe psoriasis (P = 0.786). In patients without systemic medication, allergies were found in 21.1% vs. 35.3% (P = 0.463). Conclusion: Allergy prevalence was not reduced in patients with moderate/severe psoriasis, and generally close to the prevalence in the general Austrian population (24%). The inhibiting effect of psoriasis on type 1 allergies was not confirmed. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
- Author
-
Kiltz, Uta, Sfikakis, Petros P., Gaffney, Karl, Sator, Paul-Gunther, von Kiedrowski, Ralph, Bounas, Andreas, Gullick, Nicola, Conrad, Curdin, Rigopoulos, Dimitris, Lespessailles, Eric, Romanelli, Marco, Ghislain, Pierre-Dominique, Brandt-Jürgens, Jan, Rashkov, Rasho, Aassi, Maher, Orsenigo, Roberto, Perella, Chiara, Pournara, Effie, Gathmann, Sven, and Jagiello, Piotr
- Abstract
Introduction: Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term clinical responses and a consistently favourable safety profile across phase 3 trials. Here, we report the clinical data at enrolment from SERENA, designed to investigate the real-world use of secukinumab across all three indications.Methods: SERENA is an ongoing, longitudinal, observational study conducted at 438 sites across Europe in patients with moderate to severe plaque PsO, active PsA or active AS. Patients should have received at least 16 weeks of secukinumab treatment before enrolment in the study.Results: Overall 2800 patients were included in the safety set; patients with PsA (N = 541) were older than patients with PsO (N = 1799) and patients with AS (N = 460); patients with PsO had a higher mean body weight than patients with PsA and patients with AS; and patients with PsO and patients with AS were predominantly male. Time since diagnosis was longer in patients with PsO compared with patients with PsA and patients with AS, and about 40% of patients were either current or former smokers. The proportion of obese patients (body mass index ≥ 30 kg/m2) was similar across indications. Patients were treated with secukinumab for a mean duration of 1 year prior to enrolment (range 0.89-1.04). The percentages of patients with prior biologics exposure were 31.5% PsO, 59.7% PsA and 55% AS. The percentages of patients prescribed secukinumab monotherapy were 75% (n = 1349) in PsO, 48.2% (n = 261) in PsA and 48.9% (n = 225) in AS groups.Conclusion: Baseline demographics of the study population are consistent with existing literature. This large observational study across all secukinumab indications will provide valuable information on the long-term effectiveness and safety of secukinumab in the real-world setting. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Dimethyl fumarate is efficacious in severe plaque psoriasis: Post hoc analysis from the BRIDGE trial in Austria.
- Author
-
Sator, Paul, Loewe, Robert, Zamani, Omid, Holzer, Gregor, Wolf, Peter, Mlynek, Alexander, Berger, Thomas, Richter, Leo, and Schuller, Elisabeth
- Abstract
Summary: Background: Fumaric acid esters are recommended in European guidelines for induction and maintenance treatment of patients with moderate to severe plaque psoriasis. A systemic medication with pure dimethyl fumarate without monoethyl fumarate salts was recently licensed in Europe. Objective: The efficacy and safety of pure dimethyl fumarate were assessed in patients with severe (physician global assessment) plaque psoriasis in Austria in the BRIDGE trial. Methods: In this double blind, randomized, placebo-controlled trial patients received 16-week treatment with pure dimethyl fumarate in a head to head comparison with dimethyl fumarate with monoethyl fumarate salts, which is licensed in Germany. In this post hoc analysis the efficacy and safety were assessed in patients with severe psoriasis in Austria. Results: Efficacy measures significantly improved in both active treatment arms compared to placebo in 65 patients after 16 weeks of treatment. Physician global assessment of clear/almost clear in the dimethyl fumarate group was non-inferior to the dimethyl fumarate with monoethyl fumarate salts group 2 months after end of treatment. No serious adverse reaction occurred in patients with dimethyl fumarate in contrast to the second active treatment. Efficacy outcome was paralleled by quality of life improvements. Conclusion: This is the first report of dimethyl fumarate in a severely affected population with plaque psoriasis. Dimethyl fumarate is effective and safe in the systemic treatment of adults with severe psoriasis (physician global assessment). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross‐sectional survey.
- Author
-
Wolf, Peter, Weger, Wolfgang, Legat, Franz, Painsi, Clemens, Saxinger, Werner, Müllegger, Robert, Sator, Paul, Ratzinger, Gudrun, Selhofer, Sylvia, Richter, Leo, Salmhofer, Wolfgang, Lange‐Asschenfeldt, Bernhard, Trautinger, Franz, Mlynek, Alexander, Strohal, Robert, Augustin, Matthias, and Quehenberger, Franz
- Abstract
Summary: Background: Patients with psoriasis experience impairment in quality of life. Thus, high‐quality dermatological care is of particular importance. Patients and methods: We performed a nationwide cross‐sectional survey in Austria (BQSAustria Psoriasis 2014/2015) with a special focus on quality of life and satisfaction with treatment among psoriasis patients predominantly treated at tertiary care centers. Results: Overall, 70.2 % of 1,184 patients reported impaired quality of life (DLQI 2–5: 29.4 %; 6–10: 19.3 %; 11–15: 11.5 %; 16–20: 5.2 % and > 20: 4.9 %) despite treatment over the preceding four weeks (topical treatment in 88.2 % of cases and/or systemic treatment in 38.7 %). On average, none of the 25 defined subjective treatment goals was achieved to a sufficient degree. In particular, 82.2 % of patients continued to have pruritus despite treatment, which was highly significantly associated with a poor general health status over the preceding week (Spearman's rank correlation; p = 1.1e‐45), the extent of body surface area (p = 3.2e‐11) and scalp area (p = 3.2e‐11) affected, as well as pain (p = 2.3e‐22). Treatment with a biologic was significantly correlated with higher patient satisfaction (Wilcoxon‐Test, p = 2.0e‐16). Conclusions: Despite dermatological care, the majority of Austrian psoriasis patients continues to experience impaired quality of life; there is potential for improvement in the achievement of treatment goals. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Lebensqualität und Behandlungsziele bei Psoriasis aus Patientensicht: Ergebnisse eines österreichweiten Querschnitt‐Survey.
- Author
-
Wolf, Peter, Weger, Wolfgang, Legat, Franz, Painsi, Clemens, Saxinger, Werner, Müllegger, Robert, Sator, Paul, Ratzinger, Gudrun, Selhofer, Sylvia, Richter, Leo, Salmhofer, Wolfgang, Lange‐Asschenfeldt, Bernhard, Trautinger, Franz, Mlynek, Alexander, Strohal, Robert, Augustin, Matthias, and Quehenberger, Franz
- Abstract
Zusammenfassung: Hintergrund: Patienten mit Psoriasis sind mit einer krankheitsbedingten Einschränkung ihrer Lebensqualität konfrontiert, weshalb einer hochqualitativen dermatologischen Versorgung ein besonderer Stellenwert zukommt. Patienten und Methodik: Wir führten einen bundesweiten Querschnitt‐Survey in Österreich (BQSAustria Psoriasis 2014/2015) mit dem Schwerpunkt auf Lebensqualität und Therapiezufriedenheit bei Patienten mit Psoriasis in dermatologischer Behandlung vorwiegend an Zentren mit überwiegend tertiären Versorgungsaufgaben durch. Ergebnisse: 70,2 % der 1184 befragten Patienten berichtete über eine eingeschränkte Lebensqualität (DLQI 2–5: 29,4 %; 6–10: 19,3 %; 11–15: 11,5 %; 16–20: 5,2 % und > 20: 4,9 %) trotz Behandlung innerhalb der letzten vier Wochen (mit lokaler Therapie in 88,2 % und/oder systemischer Therapie in 38,7 % der Fälle). Mit den verabreichten Therapien konnte im Durchschnitt kein einziges von 25 definierten subjektiven Behandlungszielen im gewünschten Ausmaß erreicht werden. So litten 82,2 % der Patienten trotz Behandlung weiter unter Juckreiz, wobei statistisch hochsignifikante Assoziationen mit einem schlechten Gesundheitszustand in der letzten Woche (Spearman‐Rangkorrelation; p = 1.1e‐45), dem Ausmaß des psoriatischen Körperoberflächenbefalls (p = 3.2e‐11) und Kopfhautbefalls (p = 3.2e‐11) sowie Schmerzen (p = 2.3e‐22) vorlagen. Die Behandlung mit einem Biologikum war mit einer signifikant höheren Patientenzufriedenheit verbunden (Wilcoxon‐Test, p = 2.0e‐16). Schlussfolgerungen: Die Lebensqualität der meisten österreichischen Patienten mit Psoriasis in dermatologischer Versorgung ist krankheitsbedingt beeinträchtigt, und es besteht ein Verbesserungspotenzial bei der Umsetzung von Behandlungszielen. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.
- Author
-
Sator, Paul
- Published
- 2018
- Full Text
- View/download PDF
16. Quantity and quality of sweating in atopic dermatitis.
- Author
-
Wruhs, Marlies, Gleiß, Andreas, Steiner, Andreas, and Sator, Paul
- Subjects
ATOPIC dermatitis ,HYPERHIDROSIS ,PERSPIRATION ,SKIN diseases ,ADRENOCORTICAL hormones - Abstract
Sweat may be an important factor in triggering an exacerbation of atopic dermatitis. It was the aim of this study to evaluate a possible correlation between atopic patients and hyperhidrosis-measured by a questionnaire-and to find out whether there are qualitative differences in sweat response-measured by sudomotor activity (sympathetic skin response test, SSR). Included were 100 study participants, of whom 50 were patients with atopic dermatitis and 50 were serving as control group. The frequency of hyperhidrosis is higher in atopic patients than in the control group (30 vs. 16%), but has no statistical significance. In addition, patients with hyperhidrosis and atopic dermatitis have a significantly higher exacerbation rate of atopic dermatitis in summertime. The group of atopic patients shows a statistically significant prolonged SSR latency period, which indicates an insufficient sympathetic innervation. In our tests, type IV allergic patients showed clear differences in terms of SSR latency and amplitude. Atopic patients have a higher incidence of hyperhidrosis. The study clearly shows that there is a dysfunction of sudomotor activity in the sympathetic nervous system of atopic patients. Our findings suggest that a deficient innervation of sweat glands in atopic patients may lead to an increase in the development of type IV allergies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Wundtherapie - eine Expertise der Dermatologie?!
- Author
-
Breier, Friedrich, Feldmann, Robert, Sator, Paul, and Wöhrer, Christian
- Published
- 2016
- Full Text
- View/download PDF
18. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
- Author
-
INZINGER, Martin, WIPPEL-SLUPETZKY, Katharina, WEGER, Wolfgang, RICHTER, Leo, MLYNEK, Alexander, FLEISCHANDERL, Barbara, SCHEURECKER, Christine, SANDOR, Nicolaus, MAIRHOFER, Daniela, SATOR, Paul G., MOSER-OBERTHALER, Sabine, HÄRING, Nina, VIZNEROVA, Petra, PAINSI, Clemens, TANEW, Adrian, PONHOLZER, Peter, TATARSKI, Rafaella, BRENNER, Wilhelm, STINGL, Georg, and SALMHOFER, Wolfgang
- Subjects
PSORIASIS treatment ,DRUG efficacy ,TUMOR necrosis factors ,ADALIMUMAB ,INFLIXIMAB ,ETANERCEPT - Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p = 2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Necrobiotic xanthogranuloma and polymyositis in a patient with squamous cell lung cancer: a new paraneoplastic entity?
- Author
-
RAMIC, Lejla, STEINER, Andreas, BREIER, Friedrich, KUTZNER, Heinz, SATOR, Paul, and FELDMANN, Robert
- Published
- 2020
- Full Text
- View/download PDF
20. Serum Levels of Glycoprotein Dickkopf-1 in Patients with Cutaneous Malignant Melanoma: A Prospective Pilot Study.
- Author
-
Feldmann, Robert, Schierl, Michael, Fink, Astrid M., Sator, Paul-Gunther, Maiweg, Jacob, and Steiner, Andreas
- Abstract
Background: Dickkopf-1 (Dkk-1) glycoprotein is an inhibitor of the canonical Wnt pathway. Recent studies have demonstrated elevated Dkk-1 serum levels in patients with diverse malignancies. In vitro studies with melanoma cell lines showed that loss of Dkk-1 expression may contribute to tumor progression. Objective: The present study is the first in vivo investigation of Dkk-1 serum levels in patients with cutaneous malignant melanoma. Methods: We analyzed serum levels of Dkk-1 protein in 82 patients with cutaneous melanoma. Results: Serum levels were significantly increased (mean 83.01 pmol/l) in comparison to healthy controls (mean 29.36 pmol/l). No statistical difference in Dkk-1 serum levels neither between patients without or with lymph node metastases (p = 0.719) nor between patients with or without visceral metastases (p = 0.929) was found. Patients before excision had moderately higher Dkk-1 serum levels than after excision or with florid metastases. Conclusion: Our data suggest that increased Dkk-1 expression is an early event in melanoma, decreasing in later tumor stages. It was shown previously that Dkk-1 activates cell death in melanoma cells. Our in vivo data indicate that a decrease in Dkk-1 could be a sign of loss of tumor control. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
21. Skin treatments and dermatological procedures to promote youthful skin.
- Author
-
Sator, Paul G.
- Published
- 2006
22. Skin aging and sex hormones in women– clinical perspectives for intervention by hormone replacement therapy.
- Author
-
Sator, Paul-G., Schmidt, Jolanta B., Rabe, Thomas, and Zouboulis, Christos C.
- Subjects
SKIN aging ,SEX hormones ,STEROID hormones ,ESTROGEN ,DENDRITIC cells ,HORMONE therapy - Abstract
Sator P-G, Schmidt JB, Rabe T, Zouboulis ChC. Skin aging and sex hormones in women– clinical perspectives for intervention by hormone replacement therapy.Exp Dermatol 2004: 13 (Suppl. 4): 36–40.© Blackwell Munksgaard, 2004The skin, the largest organ of the body, is the organ in which changes associated with aging are most visible. The skin is a target organ for various hormones, and sex steroids have a profound influence on the aging process. A decrease in sex steroids thus induces a reduction of those skin functions that are under hormonal control. Keratinocytes, Langerhans' cells, melanocytes, sebaceous glands, collagen content and the synthesis of hyaluronic acid, for example, are under hormonal influence. Topical application of estrogens has a positive effect on skin aging parameters, whilst numerous studies have also shown the positive influence of systemic hormone replacement therapy on skin aging. As an alternative treatment, phytohormones may be administered, with the structural similarity to 17β-estradiol explaining their estrogen-like effects. However, isoflavonoids exhibit an inferior biological potency to synthetic estrogens. Although a large number of publications have documented the effects of sex hormones on the aging process, it is obvious that hormone replacement should not be administered as an independent treatment for skin aging. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
23. Schönlein-Henoch purpura during pregnancy with successful outcome for mother and newborn.
- Author
-
Feldman, Robert, Rieger, Walter, Sator, Paul G., Gschnait, Freidrich, and Breier, Friedrich
- Subjects
PURPURA (Pathology) ,PREGNANCY ,VASCULITIS ,ADRENOCORTICAL hormones ,MOTHERS ,NEWBORN infants - Abstract
Background: Schönlein-Henoch purpura is a systemic vasculitis that affects vessels of a small caliber and rarely reported in the literature. Case presentation: We report on a 35-year-old woman who developed palpable purpura with necrotizing cutaneous lesions on the lower limbs at 27 weeks of gestation. She also complained of epigastric pain and arthralgias. Histologic examination of a skin biopsy showed leukocytoclastic vasculitis with intravascular fibrin thrombi. The direct immunofluorescence analysis evidenced vascular deposits of IgA and C3 in the upper and mid-dermis. These findings were consistent with Schönlein-Henoch purpura. There was no evidence of renal involvement or placental dysfunction. The patient was treated with low-dose oral corticosteroids and a healthy infant was delivered by cesarean section. Examination of the placenta and the navel string disclosed no signs of vasculitis or infarction. Conclusions: Schönlein-Henoch purpura is rarely reported in pregnancy. Treatment with orally administred corticosteroids may lead to a beneficial outcome for mother and newborn. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
24. Successful Treatment of Poststreptococcal Scleredema Adultorum Buschke With Intravenous Immunoglobulins.
- Author
-
Aichelburg, Maximilian C., Loewe, Robert, Schicher, Nikolaus, Sator, Paul-Gunther, Karlhofer, Franz M., Stingl, Georg, and Jalili, Ahmad
- Published
- 2012
- Full Text
- View/download PDF
25. Schönlein-Henoch purpura during pregnancy with successful outcome for mother and newborn.
- Author
-
Feldmann, Robert, Rieger, Walter, Sator, Paul G, Gschnait, Friedrich, and Breier, Friedrich
- Abstract
Background: Schönlein-Henoch purpura is a systemic vasculitis that affects vessels of a small caliber and rarely reported in the literature.Case Presentation: We report on a 35-year-old woman who developed palpable purpura with necrotizing cutaneous lesions on the lower limbs at 27 weeks of gestation. She also complained of epigastric pain and arthralgias. Histologic examination of a skin biopsy showed leukocytoclastic vasculitis with intravascular fibrin thrombi. The direct immunofluorescence analysis evidenced vascular deposits of IgA and C3 in the upper and mid-dermis. These findings were consistent with Schönlein-Henoch purpura. There was no evidence of renal involvement or placental dysfunction. The patient was treated with low-dose oral corticosteroids and a healthy infant was delivered by cesarean section. Examination of the placenta and the navel string disclosed no signs of vasculitis or infarction.Conclusion: Schönlein-Henoch purpura is rarely reported in pregnancy. Treatment with orally administered corticosteroids may lead to a beneficial outcome for mother and newborn. [ABSTRACT FROM AUTHOR]- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.